Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: what we already know and what we would like to know
Interstitial lung diseases (ILDs) represent a broad category of fibrotic pulmonary diseases and are frequently present in the course of various connective tissue diseases (CTDs), especially Systemic Sclerosis (SSc) and Rheumatoid Arthritis (RA). Despite intensive research in the field, pathogenesis is incompletely understood, and therapeutic options are limited to immunosuppressants and antifibrotic drugs. The current commentary focuses on a recent publication regarding the efficacy and safety of the anti-fibrotic drug nintedanib in patients with autoimmune related ILD with progressive fibrotic phenotype. We further discuss the important findings of this study and also point to what we still need to know
Primary Content – Primary Content Goes Here.
Close
Τα cookies είναι σημαντικά για την εύρυθμη λειτουργία του ιστοτόπου και την βελτίωση της online εμπειρίας σας. Πατήστε "Αποδοχή" για να συνεχίσετε!
